Despite Progress in Safe Drinking Water & Sanitation, Billions Still Lack Coverage 19/06/2019 Editorial team The proportion of the world’s population using safely managed sanitation services increased from 28-45% between 2000 and 2017, according to the latest joint report of the World Health Organization and UNICEF on Progress in Household Drinking Water, Sanitation and Hygiene. However, huge service gaps still remain, with 4.2 billion people worldwide still lacking access to […] Continue reading -> US-Venezuela Tensions Simmer At World Health Assembly, While Global Community Scales Up Emergency Medical Aid 26/05/2019 John Zarocostas Mounting political tensions between the United States and the embattled Venezuelan government of President Nicolás Maduro, including a proliferation of crippling US sanctions, are being played out in the halls of the 72nd World Health Assembly, marred by walkouts and finger-pointing by the two adversaries. Image Credits: WHO/PAHO, John Zarocostas. Continue reading -> Following 110 years of neglect, an official day for Chagas disease is declared 24/05/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 24 May 2019 The delegates at the World Health Assembly (WHA) have today approved the creation of a World Chagas Day. People affected by Chagas worldwide celebrate this important step in fighting for recognition of this neglected disease. Image Credits: DNDi. Continue reading -> New Study Maps Vaccine Coverage Disparities, Helps Explain Why Targets Are Being Missed 26/04/2019 Maina Waruru Child vaccination targets of at least 80 percent coverage in low- and middle-income countries, are regularly being missed. To better understand why this is happening, a new study created high resolution maps of vaccine coverage to identify disparities within countries and to inform effective strategies to increase coverage and access. Image Credits: WHO. Continue reading -> PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
US-Venezuela Tensions Simmer At World Health Assembly, While Global Community Scales Up Emergency Medical Aid 26/05/2019 John Zarocostas Mounting political tensions between the United States and the embattled Venezuelan government of President Nicolás Maduro, including a proliferation of crippling US sanctions, are being played out in the halls of the 72nd World Health Assembly, marred by walkouts and finger-pointing by the two adversaries. Image Credits: WHO/PAHO, John Zarocostas. Continue reading -> Following 110 years of neglect, an official day for Chagas disease is declared 24/05/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 24 May 2019 The delegates at the World Health Assembly (WHA) have today approved the creation of a World Chagas Day. People affected by Chagas worldwide celebrate this important step in fighting for recognition of this neglected disease. Image Credits: DNDi. Continue reading -> New Study Maps Vaccine Coverage Disparities, Helps Explain Why Targets Are Being Missed 26/04/2019 Maina Waruru Child vaccination targets of at least 80 percent coverage in low- and middle-income countries, are regularly being missed. To better understand why this is happening, a new study created high resolution maps of vaccine coverage to identify disparities within countries and to inform effective strategies to increase coverage and access. Image Credits: WHO. Continue reading -> PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Following 110 years of neglect, an official day for Chagas disease is declared 24/05/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 24 May 2019 The delegates at the World Health Assembly (WHA) have today approved the creation of a World Chagas Day. People affected by Chagas worldwide celebrate this important step in fighting for recognition of this neglected disease. Image Credits: DNDi. Continue reading -> New Study Maps Vaccine Coverage Disparities, Helps Explain Why Targets Are Being Missed 26/04/2019 Maina Waruru Child vaccination targets of at least 80 percent coverage in low- and middle-income countries, are regularly being missed. To better understand why this is happening, a new study created high resolution maps of vaccine coverage to identify disparities within countries and to inform effective strategies to increase coverage and access. Image Credits: WHO. Continue reading -> PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New Study Maps Vaccine Coverage Disparities, Helps Explain Why Targets Are Being Missed 26/04/2019 Maina Waruru Child vaccination targets of at least 80 percent coverage in low- and middle-income countries, are regularly being missed. To better understand why this is happening, a new study created high resolution maps of vaccine coverage to identify disparities within countries and to inform effective strategies to increase coverage and access. Image Credits: WHO. Continue reading -> PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Posts navigation Older postsNewer posts